Funding approved for Avelumab in combination with Axitinib

  KCSN are formal consultees to N I C E and part of the process that appraises all new kidney cancer drugs.  We are delighted to tell you that, as from today, kidney cancer patients can get NHS funding via the Cancer Drugs Fund for Avelumab in combination with Axitinib as a 1st line treatment for […]

read more

Axitinib first-line treatment of papillary renal cell carcinoma

The majority of renal cell carcinomas (RCCs) are a subtype called clear cell RCC. Most drugs have been developed to treat this subtype of RCC, leaving people with other metastatic RCC subtypes with an unmet need for an effective treatment in the first-line. Papillary RCC (pRCC) represents 10-15% of renal cell carcinomas, and is not an insignificant subtype. […]

read more

Individualised axitinib dosing for patients with metastatic kidney cancer

In the following video interview with Practice Update, Dr Nancy Davis from Vanderbilt University Medical Center in Nashville, Tennessee, USA talks about a study looking at individualised dosing of axitinib for patients with metastatic renal cell carcinoma (RCC) based on toxicity. This was a single-arm study in patients with metastatic predominately clear cell RCC who […]

read more

Safety and efficacy of restarting immune checkpoint inhibitors after immune-related adverse events

Immune checkpoint inhibitors can cause a number of immune-related adverse events (irAEs) of various degrees of severity, such as colitis, pneumonitis, hypothyroidism, liver problems and skin rashes. A recent multi-centre, retrospective study published in Journal for Immunotherapy of Cancer investigated the safety and efficacy of re-treatment with immune checkpoint inhibitors, such as nivolumab and ipilimumab […]

read more

Promising activity of pembrolizumab plus bevacizumab for metastatic kidney cancer

Results from a phase Ib/II study published in Journal of Clinical Oncology last month show encouraging activity of a novel immunotherapy and VEGF inhibitor combination in metastatic renal cell carcinoma (mRCC). In the phase Ib part of the study, which was used to find the safest and most tolerated dose of the combination, there were […]

read more

ASCO GU 2020: VEGF tyrosine kinase inhibitors as second-line treatment after immunotherapy for advanced kidney cancer

A retrospective analysis of data from the International Metastatic Renal Cell Carcinoma Database Consortium (IMDC) was presented at the American Society for Clinical Oncology (ASCO) Genitourinary (GU) Cancers Symposium in San Francisco from 13-15 February. The analysis looked at response rates and survival of metastatic renal cell carcinoma (RCC) patients who had been treated with […]

read more

Evaluation of brain metastases in patients with kidney cancer treated with avelumab plus axitinib

In this video interview from Practice Update, Dr Eric Jonasch from MD Anderson Cancer Center in the USA talks about some interesting data on brain metastases in patients who have received a combination therapy. Renal cell carcinoma (RCC) patients will develop brain metastases in about 10% to 20% of the time, and the treatment for […]

read more

Novel HIF-2a inhibitor for patients with advanced kidney cancer

In this interview with Practice Update, Dr Eric Jonasch from MD Anderson Cancer Center in the USA talks about the the novel hypoxia inducible factor (HIF)-2 alpha inhibitor for the treatment of previously treated advanced renal cell carcinoma (RCC). Dr Jonasch described how HIF-2 alpha works and then went on to talk about the results […]

read more

ASCO GU Cancers Symposium Highlights 2020

Over 4,000 delegates attended the American Society of Clinical Oncology (ASCO) Genitourinary (GU) Cancers Symposium in San Francisco, 13-15 February 2020. The International Kidney Cancer Coalition (IKCC) was present with a booth to raise awareness, and also attended many of the medical and patient advocacy sessions. The past couple of years have been watershed years […]

read more

ASCO GU 2020: Immunotherapy combinations effective for brain metastases

Two small studies reported on patients whose kidney cancer had spread into the brain at the American Society of Clinical Oncology (ASCO) Genitourinary (GU) Cancers Symposium held in San Francisco last weekend. The first study was a real-world report of 17 patients with advanced kidney cancer in the brain. The patients were treated with ipilimumab and […]

read more
Showing 1 to 10 of 456 results
  TOP